● Recruiting

A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics for a Single Dose of HRS-9821 Powder for Inhalation and Inhalation Suspension Administered in Healthy Subjects and Multiple Doses in Patients With COPD.

Condition: COPD · Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd

PhasePhase 1

Planned participants160

Who can joinAll sexes, 18 Years to 75 Years

Healthy volunteersYes

About this study

The aim of this study was to evaluate the safety and tolerability of HRS-9821 Powder for Inhalation and inhalation suspension administered in a single dose in healthy individuals and multiple doses in patients with COPD

This description comes directly from the study's public registry record.

Talk to the study team

Huanhuan Huang · +0518-81220121 · huanhuan.huang.hh30@hengrui.com

Always discuss trial participation with your own doctor first.

Locations (1)

West China Hospital, Sichuan University

Chengdu, Sichuan, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07116915